Advanced Accelerator Applications, a Novartis Company is an innovative medicines company focused on the development of targeted radioligand therapies and precision imaging radioligands for oncology. Radioligand therapy (RLT) is a targeted drug containing a radioactive particle that binds to specific receptors on cancer cells, damaging the cell and/or triggering cell death. Advanced Accelerator Applications also has an active research and development pipeline of investigational drugs using radiolabeled targeting molecules in multiple cancer types. The company employs 1,000 associates across 31 sites in 12 countries.
Brands: LUTATHERA® (lutetium Lu 177 dotatate),
NETSPOT® (kit for the preparation of gallium Ga 68 dotatate injection)
Pluvicto ® (lutetium Lu 177 vipivotide tetraxetan)
Locametz ® (kit for the preparation of gallium Ga 68 gozetotide injection)